Imbruvica/Venclyxto tops Gazyva plus chemo in first-line CLL/SLL
Imbruvica treatment regimen demonstrated superior progression-free survival compared to Gazyva combo
Read More
Tag: Imbruvica
Calquence tops Imbruvica in chronic lymphocytic leukaemia study
BTK inhibitor demonstrated non-inferior progression-free survival compared to Imbruvica
Read More
Bavencio, Imbruvica among latest SMC decisions
The committee accepted a number of drugs through the PACE process
Read More
EU expands scope of Imbruvica to include untreated CLL patients
Treatment naïve patients lived longer without disease progression with the Imbruvica-based regimen than those given a chemotherapy-based one
Read More
Imbruvica bags EU expansion for two indications
The approval follows the Positive Opinion from the European Medicines Agency’s CHMP, and marks the fifth European approval in as many years.
Read More
FDA approves Imbruvica combination for chronic lymphocytic leukaemia
The FDA has approved AbbVie/Johnson & Johnson’s Imbruvica in combination with Roche’s Gazyva in treatment-naïve patients with chronic lymphocytic leukaemia and small lymphocytic lymphoma (CLL/SLL).
Read More
Imbruvica fails Phase III pancreatic cancer trial
A late-stage trial testing AbbVie’s Imbruvica in combination with chemotherapy for metastatic pancreatic adenocarcinoma (cancer) has failed to meet its primary endpoint.
Read More
AbbVie, J&J’s Imbruvica fails to target in B-Cell lymphoma trial
AbbVie and Johnson & Johnson’s Imbruvica has failed to meet its key target in a late stage study assessing its use in patients with treatment-naïve diffuse large B-cell lymphoma.
Read More
Imbruvica/Gazyva combo improves PFS in CLL patients
A combination of AbbVie/Johnson & Johnson’s Imbruvica and Roche’s Gazyva has taken a step closer to becoming first chemotherapy-free CD20 combination for first-line treatment of chronic lymphocytic leukaemia (CLL), after showing promise in a late-stage clinical trial.
Read More
Final NHS nod for Janssen’s Imbruvica
Janssen’s Imbruvica will be routinely available on the NHS to treat certain patients with mantle cell lymphoma (MCL), after cost regulators issued a final green light for the drug.
Read More
NICE recommends Imbruvica for some MCL patients
It is looking likely that a subgroup of patients with mantle cell lymphoma (MCL) will get routine access to Janssen’s Imbruvica on the NHS.
Read More
FDA green lights first treatment for chronic GvHD
The US Food and Drug Administration has expanded the scope of Johnson & Johnson/AbbVie’s Imbruvica to include the treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more treatments, marking the first therapy specifically approved for the condition in the US.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
